Biofrontera Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; this filing reports annual results, not standalone fourth-quarter results. The audited financial statements received an unqualified audit opinion. Biofrontera is a U.S. biopharmaceutical commercial-stage company whose revenue is primarily from licensed Ameluz photodynamic therapy (PDT) products for actinic keratosis; Xepi, for impetigo, contributed relatively little. Biofrontera AG, a related party, owned 26.4% at year-end.
Financial performance and position
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Net revenue | $34.1 million | $28.7 million | Up 18.8%; product revenue rose 19.1% to $34.0 million |
| Gross profit and margin | Approximately $16.6 million; 48.8% | Approximately $13.5 million; 47.1% | Calculated from reported revenue less cost of revenue |
| Operating loss | $22.7 million | $18.6 million | Loss widened $4.1 million |
| Net loss | $20.1 million | $0.6 million | Widened substantially; 2022 included a larger noncash warrant fair-value gain |
| Adjusted EBITDA | $(19.5) million | $(18.1) million | Non-GAAP; margin improved to (57.1%) from (63.0%) as revenue growth outpaced adjusted EBITDA deterioration |
| Cash used in operations | $24.9 million | $16.2 million | Cash burn increased |
| Cash and cash equivalents at year-end | $1.3 million | $17.2 million | Down $15.9 million; cash-flow statement reports $1.5 million including restricted cash |
| Total assets / liabilities / equity | $27.9 million / $23.1 million / $4.8 million | $50.9 million / $27.0 million / $23.9 million | Equity declined materially |
Ameluz sales growth was principally attributed to salesforce expansion and increased order volume, with a smaller contribution from price. SG&A rose 10.9% to $39.0 million, including higher personnel, commercial, clinical-grant and legal costs. The reported net loss also reflected a $7.4 million loss on Biofrontera AG investment value, partly offset by a $7.4 million gain on the Maruho settlement and a $6.5 million noncash gain from changes in warrant-liability fair value.
At December 31, current assets were $23.1 million and current liabilities $18.1 million. Inventory was $10.9 million, including a $5.2 million write-off for recalled Ameluz lots, offset by an asset for expected replacement product. Year-end short-term debt was $3.9 million. Two secured loans had a stated 44% interest rate at year-end and required weekly principal-and-interest payments of approximately $102,857 through July 5, 2024. The revolving credit facility was repaid and terminated in January 2024.
Material changes and notable developments
- Revenue increased, but operating expenses grew faster, widening the operating loss. Operating cash outflow also increased.
- In December 2023, the Company settled its dispute with Maruho: it transferred Biofrontera AG shares and was released from $7.3 million of start-up financing repayment and contingent profit-sharing obligations. The exchange generated a $7.4 million accounting gain; the obligations’ release is not recurring operating income.
- In February 2024, the Ameluz license and supply agreement was revised: the transfer price is 25% for 2024–2025, with scheduled increases to a maximum of 35% from 2032 for specified indications. Management expects approximately 75% Ameluz gross margins on future purchases, versus the prior stated 50% transfer-price basis; it says the savings are partly offset by R&D costs and expects net savings of about $0.7 million by March 2025. The filing says the benefit is not expected until Ameluz inventory orders for delivery in Q4 2024.
- The Company expects to assume responsibility for ongoing U.S. Ameluz clinical trials by June 1, 2024. Management says the revised transfer pricing is intended to help fund these activities.
Outlook, risks and contingencies
Management provided no formal numerical revenue or earnings guidance. Its liquidity plan depends on execution of the 2024 budget, cost control, sales growth and financing. Management stated that discretionary spending in the 2024 budget is about $5.5 million below 2023 levels. A stated financing condition includes at least 5% year-to-date revenue growth versus the comparable 2023 period, alongside other milestones.
The filing identifies substantial doubt about the Company’s ability to continue as a going concern, while management believes its plans alleviate that doubt. Cash was approximately $4.1 million as of March 11, 2024, unaudited. The Company received approximately $7.2 million net from a February 2024 preferred-stock financing; a further warrant exercise could provide additional proceeds, but depends on conditions including revenue and commercial-system targets, stockholder approval and registration effectiveness. Management cautions that financing may not occur as expected and additional capital may be needed.
- Supply and product execution: Biofrontera relies on licensors and contract manufacturers. Xepi commercialization has been constrained by manufacturer problems; a replacement manufacturer was expected to begin production in the second half of 2024. RhodoLED XL launch was anticipated around Q2 2024, subject to supply timing.
- Recall: The Ameluz licensor initiated a February 2024 voluntary recall of limited lots because of a packaging defect. The licensor said adverse health consequences were unlikely; customers were notified and replacements arranged. The Company said it does not expect a material financial impact.
- Litigation: DUSA and Sun entities allege breach of contract, Lanham Act violations and unfair trade practices related to Ameluz promotion. Biofrontera denies the claims; at the filing date it could not estimate the likelihood or range of loss. An adverse outcome could materially affect results, financial position or cash flows.
- Listing and dilution: Nasdaq notified the Company that it did not meet continued listing standards, including the minimum stockholders’ equity requirement. Nasdaq accepted a compliance plan and allowed 180 days from November 22, 2023 to demonstrate compliance. Preferred stock and warrants could create substantial dilution; the additional warrant financing also depends on sufficient authorized common shares and stockholder approval.
- Other key exposures: Dependence on Ameluz, competition and potential generics, reimbursement and pricing changes, license termination, related-party reliance, clinical and regulatory uncertainty, and the possibility that warrant fair-value changes cause significant noncash earnings volatility.
Most important facts for investors to verify
- Whether operating cash burn and spending reductions are consistent with the Company’s liquidity plan, and whether the conditional warrant financing was completed.
- Nasdaq compliance status, stockholder approval for authorized shares, and the resulting preferred-stock and warrant dilution.
- Actual Ameluz transfer prices, inventory purchases, realized gross margins and timing of savings under the amended agreement.
- Whether Xepi supply resumed and RhodoLED XL shipments and launch occurred on the stated timelines.
- Developments in the DUSA litigation and the scope, replacement and financial consequences of the Ameluz recall.
- Revenue and cash flow trends after 2023, distinguishing recurring commercial performance from settlement gains and noncash warrant or investment fair-value changes.